
- 2022.08.09
- The National Institute of Neurological Disorders and Stroke and SymBio Pharmaceuticals Limited will collaborate to evaluate the potential antiviral activity of brincidofovir (BCV) against Epstein Barr virus (EBV)
- 2022.08.05
- Analyst Report[Update report] (Shared Research)
- 2022.08.04
- Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
- 2022.08.04
- Revision to Earnings Forecast for FY 2022
- 2022.07.11
- SymBio announces the publication of the results of its Phase I/II clinical study of the rapid infusion (RI) administration of TREAKISYM liquid formulation
- 2022.06.16
- Notice of Resignation of Director
- 2022.06.14
- SymBio submits clinical trial notification to PMDA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation
- 2022.06.13
- SymBio announces status of market adoption of the 10-minute Rapid Infusion (RI) administration of the TREAKISYM Liquid Formulation
- 2022.06.08
- Analyst Report[Basic Report] (Fair Research)
- 2022.06.03
- Analyst Report[Full report] (Shared Research)
- 2022.06.01
- Completion of Payment for the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
- 2022.05.24
- Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
- 2022.05.18
- Chimerix announces sale of brincidofovir to Emergent BioSolutions
- 2022.05.16
- Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
- 2022.05.11
- Summary of Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
- 2022.04.22
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
- 2022.04.22
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
- 2022.04.01
- Joint research agreement with the National Cancer Center on rare cancers
- 2022.03.31
- Notice of Renewal of Syndicated Loan Agreement
- 2022.03.30
- Notice of Shareholder Voting Results for the 17th Annual General Meeting of Shareholders
- 2022.03.29
- Notice of Appointments to the Board of Directors and the Audit & Supervisory Committee, and Appointments of Corporate Officers
- 2022.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2022.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2022.03.25
- Analyst Report[Full report] (Shared Research)
- 2022.03.09
- Information on Shareholders' Meeting: Updated the Page
- 2022.03.08
- SymBio announces publication the final results of its phase 3 clinical trial of TREAKISYM in r/r DLBCL
- 2022.03.07
- SymBio announces initiation of non-clinical study of brincidofovir IV for brain tumors in collaboration with Brown University, USA
- 2022.02.28
- SymBio receives approval of TREAKISYM Liquid Formulation Rapid Infusion (RI) administration
- 2022.02.25
- Response to marketing approvals of generic products
- 2022.02.24
- Notification of Amendments to the Articles of Incorporation
- 2022.02.24
- Notice regarding the transition to a company with an audit and supervisory committee and nomination of directors
- 2022.02.24
- SymBio announces results of a collaborative study with the National Institute of Infectious Diseases on adenoviruses and the antiviral agent brincidofovir
- 2022.02.10
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2022.02.10
- Notice concerning non-operating expenses
- 2022.02.10
- Notice regarding difference between earnings forecast and the actual results for the fiscal year ended December 31, 2021
- 2022.01.31
- Initiation of a phase 2 clinical trial of bendamustine and rituximab combination therapy followed by autologous hematopoietic stem cell transplantation in patients with relapsed or refractory diffuse large B-cell lymphoma
- 2022.01.18
- SymBio submits clinical trial application to MHRA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for treatment of pediatric adenovirus infection
- 2022.01.06
- Joint research agreement to establish a Social Collaboration Course, Molecular Oncology, with the University of Tokyo
- 2021.12.24
- Notice of Appointment of Executive Vice President, Corporate Officer and COO
- 2021.12.20
- Notice of Appointment of Corporate Officer
- 2021.12.06
- Analyst Report[Follow-up Report] (Fair Research)
- 2021.12.03
- Analyst Report[Full report] (Shared Research)
- 2021.11.24
- SymBio receives approval of shelf-life extension forTREAKISYM ready-to-dilute (RTD) liquid formulation
- 2021.11.11
- Analyst Report[Update report] (Shared Research)
- 2021.11.11
- Summary of Financial Statements for the Third Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2021.11.11
- Notice Concerning Non-operating Expenses
- 2021.11.11
- SymBio Achieves Operating Profit for the Nine Months Ending December 31, 2021 Financial Overview for the Third Quarter of the Fiscal Year
- 2021.11.11
- SymBio announces selection of "Growth Market" as new market segment
- 2021.11.11
- Message from President of SymBio Pharma USA
- 2021.10.12
- SymBio announces commencement of operations of SymBio Pharma USA, Inc.
- 2021.09.29
- SymBio announces presentation of the final results of its Phase 3 Clinical Trial of TREAKISYM in r/r DLBCL at the 83rd Annual Meeting of the Japanese Society of Hematology
- 2021.09.27
- Onconova Therapeutics announces preliminary data on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
- 2021.09.21
- Initiation of controls on shipments of TREAKISYM lyophilized injection formulation
- 2021.09.09
- Analyst Report[Research Coverage Report] (Shared Research)
- 2021.09.08
- SymBio announces initiation of non-clinical study of brincidofovir IV at the Brain Tumor Center, Department of Neurological Surgery University of California, San Francisco
- 2021.09.01
- SymBio enters into a collaborative research agreement with the National Cancer Centre Singapore on Epstein-Barr virus positive lymphoma
- 2021.08.17
- SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of anti-viral drug Brincidofovir IV
- 2021.08.04
- Analyst Report[Update report] (Shared Research)
- 2021.08.04
- Notice Concerning Non-operating Expenses
- 2021.08.04
- Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2021.08.02
- Collaborative research with Kyoto University on mechanism of response of bendamustine for diffuse large B-cell lymphoma
- 2021.07.15
- Notice of Appointment of Corporate Officer
- 2021.07.15
- Collaborative research with Gunma University to explore new indications for bendamustine and rigosertib
- 2021.06.29
- Onconova Therapeutics announces an update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
- 2021.06.23
- Notice of Changes of Director
- 2021.06.18
- Onconova Therapeutics announces the synergistic anti-cancer activity of rigosertib combined with immune checkpoint blockade
- 2021.06.16
- Analyst Report[Full report] (Shared Research)
- 2021.06.07
- Chimerix receives U.S. Food and Drug Administration approval for brincidofovir for the treatment of smallpox
- 2021.06.01
- Analyst Report[Basic Report] (Fair Research)
- 2021.05.25
- New Patent Issued in Japan for Antiviral Agent Brincidofovir